DR. MARY CATHERINE FISCHER M.D.
Prescription History 1306844113
Ophthalmology in Chevy Chase, MD
Quality Rating: 100 out of 100 score
NPI Status: Active since July 14, 2005
Contact Information
2 WISCONSIN CIR STE 230
CHEVY CHASE, MD
ZIP 20815
Phone: (301) 215-7100
Fax: (240) 482-3070
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MARY CATHERINE FISCHER M.D., an active Ophthalmology specialist practicing in Chevy Chase, MD. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 69 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 35 claims alone.
Latanoprost
Generic Formulation: LatanoprostSpecialty: OphthalmologyProvider Avg Cost Per Claim
$8.38
State Avg Cost Per Claim
$21.84
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.
Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.
Tobramycin-Dexamethasone
Generic Formulation: Tobramycin/DexamethasoneSpecialty: OphthalmologyProvider Avg Cost Per Claim
$54.73
State Avg Cost Per Claim
$82.03
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.
This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MARY CATHERINE FISCHER M.D. provides transparency into local medical care patterns within Chevy Chase, MD.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
